Quantinno Capital Management LP Boosts Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Quantinno Capital Management LP boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 245.8% in the first quarter, Holdings Channel reports. The institutional investor owned 80,061 shares of the biotechnology company’s stock after purchasing an additional 56,909 shares during the period. Quantinno Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $762,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of BioCryst Pharmaceuticals by 13.8% during the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,494 shares in the last quarter. Captrust Financial Advisors raised its position in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Finally, Legato Capital Management LLC boosted its stake in BioCryst Pharmaceuticals by 10.0% in the 4th quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 2,172 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $9.70 on Wednesday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The stock has a 50-day moving average of $9.55 and a 200 day moving average of $8.88. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -6.47 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.15 EPS. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BCRX. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Wedbush dropped their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada decreased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.